Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal

References

• Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999;40:407–414. doi: 10.1016/S0010-440X(99)90082-2
   PubMed Web of Science ®Google Scholar
• Weston-Green K. Antipsychotic drug development: from historical evidence to fresh perspectives. FrontPsychiatr. 2022;13. doi: 10.3389/fpsyt.2022.903156
   Google Scholar
• Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. BrJpsychiatry Suppl. 1992;41–45. doi: 10.1192/S0007125000296918
   Google Scholar
• Copolov DL, Bell WR, Benson WJ, et al. Clozapine treatment in australia: A review of haematological monitoring. MedJaust. 1998;168:495–497. doi: 10.5694/j.1326-5377.1998.tb141414.x
   Google Scholar
• Tandon R, Lenderking WR, Weiss C, et al. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. Ann Gen Psychiatry. 2020;19:42. doi: 10.1186/s12991-020-00292-5
   PubMed Web of Science ®Google Scholar
• Potkin SG, Kane JM, Correll CU, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6:1. doi: 10.1038/s41537-019-0090-z
   PubMed Web of Science ®Google Scholar
• van Westrhenen R, Ingelman-Sundberg M. Editorial: from trial and error to individualised pharmacogenomics-based pharmacotherapy in psychiatry. Front Pharmacol. 2021;12. doi: 10.3389/fphar.2021.725565
   Web of Science ®Google Scholar
• Carlsson A. Does dopamine play a role in schizophrenia? Psychol Med. 1977;7(4):583–597. doi: 10.1017/S003329170000622X
   PubMed Web of Science ®Google Scholar
• Felder CC, Porter AC, Skillman TL, et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 2001;68(22–23):2605–2613. doi: 10.1016/s0024-3205(01)01059-1
   PubMedGoogle Scholar
• Dean B, Bymaster FP, Scarr E. Muscarinic receptors in schizophrenia. Curr Mol Med. 2003;3:419–426. doi: 10.2174/1566524033479654
   PubMed Web of Science ®Google Scholar
• Paul SM, Yohn SE, Popiolek M, et al. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179:611–627. doi: 10.1176/appi.ajp.21101083
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—an overview. JAMA Psychiatry. 2020;77:201–210. doi: 10.1001/jamapsychiatry.2019.3360
   PubMed Web of Science ®Google Scholar
• Kraguljac N, McDonald W, Widge A, et al. Neuroimaging biomarkers in schizophrenia. Am J Psychiatr. 2021;178:509–521. doi: 10.1176/appi.ajp.2020.20030340
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders fifth edition. 5. Arlington: American Psychiatric Association; 2013.
   Google Scholar
• Howes O, Fusar-Poli P, Osugo M. Treating negative symptoms of schizophrenia: Current approaches and future perspectives. Br J Psychiatry. 2023;223:332–335. doi: 10.1192/bjp.2023.57
   PubMed Web of Science ®Google Scholar
• Scarr E, Gibbons AS, Neo J, et al. Cholinergic connectivity: It’s implications for psychiatric disorders. Front Cell Neurosci. 2013;7:55. doi: 10.3389/fncel.2013.00055
   PubMed Web of Science ®Google Scholar
• Dean B, Scarr E. Muscarinic m1 and m4 receptors: Hypothesis driven drug development for schizophrenia. Psychiatry Res. 2020;288:112989. doi: 10.1016/j.psychres.2020.112989
   PubMed Web of Science ®Google Scholar
• Ogino S, Miyamoto S, Miyake N, et al. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014;68:37–49. doi: 10.1111/pcn.12088
   PubMed Web of Science ®Google Scholar
• Joshi YB, Thomas ML, Braff DL, et al. Anticholinergic medication burden–associated cognitive impairment in schizophrenia. Am J Psychiatr. 2021;178:838–847. doi: 10.1176/appi.ajp.2020.20081212
   PubMed Web of Science ®Google Scholar
• Ziskind AA. Transdermal scopolamine-induced psychosis. Postgrad Med. 1988;84:73–76. doi: 10.1080/00325481.1988.11700397
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Allen JS, Otto C, et al. Effects of chewing betel nut (areca catechu) on the symptoms of people with schizophrenia in palau, micronesia. Br J Psychiatry. 2000;177:174–178. doi: 10.1192/bjp.177.2.174
   PubMed Web of Science ®Google Scholar
• Kozlakidis Z, Cheong IH, Wang H. Betel nut and arecoline: Past, present, and future trends. Innov Digital Health Diagn Biomarkers. 2022;2:64–72. doi: 10.36401/iddb-22-05
   Google Scholar
• Shannon HE, Bymaster FP, Calligaro DO, et al. Xanomeline: A novel muscarinic receptor agonist with functional selectivity for m1 receptors. J Pharmacol Exp Ther. 1994;269:271–281.
   PubMed Web of Science ®Google Scholar
• Shannon HE, Rasmussen K, Bymaster FP, et al. Xanomeline, an m(1)/m(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42:249–259.
   PubMed Web of Science ®Google Scholar
• Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatr. 2008;165(8):1033–1039. doi: 10.1176/appi.ajp.2008.06091591
   PubMed Web of Science ®Google Scholar
• Breier A, Brannan SK, Paul SM, et al. Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacol (Berl). 2023;240:1191–1198. doi: 10.1007/s00213-023-06362-2
   PubMed Web of Science ®Google Scholar
• Correll CU, Angelov AS, Miller AC, et al. Safety and tolerability of karxt (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia. 2022;8:109. doi: 10.1038/s41537-022-00320-1
   Google Scholar
• Correll CU, Miller AC, Sawchak S, et al. Safety and efficacy of karxt (xanomeline trospium) in schizophrenia in the phase 3, randomized, double-blind, placebo-controlled emergent-2 trial. CNS Spectr. 2023;28:220–220. doi: 10.1017/S1092852923001360
   Google Scholar
• Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717–726. doi: 10.1056/NEJMoa2017015
   PubMed Web of Science ®Google Scholar
• Sauder C, Allen LA, Baker E, et al. Effectiveness of karxt (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. TransPsychiatr. 2022;12:491. doi: 10.1038/s41398-022-02254-9
   Google Scholar
• Weiden PJ, Breier A, Kavanagh S, et al. Antipsychotic efficacy of karxt (xanomeline-trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psychiatry. 2022;83:21m14316. doi: 10.4088/JCP.21m14316
   PubMed Web of Science ®Google Scholar
• Yohn SE, Weiden PJ, Felder CC, et al. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022;43:1098–1112. doi: 10.1016/j.tips.2022.09.006
   PubMed Web of Science ®Google Scholar
• Davis L. Maplight therapeutics announces completion of phase 1 clinical trial for ml-007, a novel therapy for the treatment of schizophrenia and dyskinesias. In: Maplight; 2023.
   Google Scholar
• Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405:113201. doi: 10.1016/j.bbr.2021.113201
   PubMed Web of Science ®Google Scholar
• van der Westhuizen ET, Choy KHC, Valant C, et al. Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias. Front Pharmacol. 2020;11:606656. doi: 10.3389/fphar.2020.606656
   PubMed Web of Science ®Google Scholar
• Moran SP, Maksymetz J, Conn PJ. Targeting muscarinic acetylcholine receptors for the treatment of psychiatric and neurological disorders. Trends Pharmacol Sci. 2019;40:1006–1020. doi: 10.1016/j.tips.2019.10.007
   PubMed Web of Science ®Google Scholar
• Jakubik J, El-Fakahany EE. Current advances in allosteric modulation of muscarinic receptors. Biomolecules. 2020;10. doi: 10.3390/biom10020325
   PubMed Web of Science ®Google Scholar
• Krystal JH, Kane JM, Correll CU, et al. Emraclidine, a novel positive allosteric modulator of cholinergic m4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022;400(10369):2210–2220. doi: 10.1016/S0140-6736(22)01990-0
   PubMed Web of Science ®Google Scholar
• Stuke H. Markers of muscarinic deficit for individualized treatment in schizophrenia. FrontPsychiatr. 2023;13. doi: 10.3389/fpsyt.2022.1100030
   Google Scholar
• Johnson CR, Kangas BD, Jutkiewicz EM, et al. Drug design targeting the muscarinic receptors and the implications in central nervous system disorders. Biomedicines. 2022;10(2):398. doi: 10.3390/biomedicines10020398
   PubMed Web of Science ®Google Scholar
• Nathan PJ, Watson J, Lund J, et al. The potent m(1) receptor allosteric agonist gsk1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 2013;16:721–731.
   PubMed Web of Science ®Google Scholar
• Nguyen HTM, van der Westhuizen ET, Langmead CJ, et al. Opportunities and challenges for the development of m1 muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits. Br J Pharmacol. 2022;n/a:15982. doi: 10.1111/bph.15982
   Google Scholar
• Dean B, Crook JM, Opeskin K, et al. The density of muscarinic m1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry. 1996;1:54–58.
   PubMed Web of Science ®Google Scholar
• Crook JM, Tomaskovic-Crook E, Copolov DL, et al. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of brodmann’s areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatr. 2001;158(6):918–925. doi: 10.1176/appi.ajp.158.6.918
   PubMed Web of Science ®Google Scholar
• Gibbons A, Scarr E, Boer S, et al. Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int J Neuropsychopharmacol. 2013;16(1):37–46. doi: 10.1017/S1461145712000028
   PubMed Web of Science ®Google Scholar
• Deng C, Huang XF. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res. 2005;81(6):883–890. doi: 10.1002/jnr.20600
   PubMed Web of Science ®Google Scholar
• Zavitsanou K, Katsifis A, Filomena M, et al. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacol. 2004;29:619–625.
   PubMed Web of Science ®Google Scholar
• Crook JM, Tomaskovic-Crook E, Copolov DL, et al. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatr. 2000;48:381–388.
   PubMed Web of Science ®Google Scholar
• Dean B, Gray L, Keriakous D, et al. A comparison of m1 and m4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus Relat Syst. 2004;2:287–295.
   Google Scholar
• Scarr E. Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neurosci Ther. 2012;18:369–379. doi: 10.1111/j.1755-5949.2011.00249.x
   PubMed Web of Science ®Google Scholar
• Zavitsanou K, Katsifis A, Yu Y, et al. M2/m4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain ResBull. 2005;65(5):397–403. doi: 10.1016/j.brainresbull.2005.02.007
   PubMed Web of Science ®Google Scholar
• Gibbons AS, Scarr E, McLean C, et al. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord. 2009;116(3):184–191. doi: 10.1016/j.jad.2008.11.015
   PubMed Web of Science ®Google Scholar
• Scarr E, McLean C, Dean B. Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with alzheimer’s disease. J Neural Transm. 2017;124:273–284. doi: 10.1007/s00702-016-1625-3
   PubMed Web of Science ®Google Scholar
• McOmish C, Pavey G, McLean C, et al. Muscarinic receptor binding changes in postmortem parkinson’s disease. J Neural Transm. 2017;124:227–236. doi: 10.1007/s00702-016-1629-z
   PubMed Web of Science ®Google Scholar
• Dean B, McLeod M, Keriakous D, et al. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2002;7:1083–1091.
   PubMed Web of Science ®Google Scholar
• Mancama D, Arranz MJ, Landau S, et al. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B: Neuropsych Genet. 2003;119:2–6.
   Google Scholar
• Scarr E, Sundram S, Keriakous D, et al. Altered hippocampal muscarinic m4, but not m1, receptor expression from subjects with schizophrenia. Biol Psychiatr. 2007;61:1161–1170.
   PubMed Web of Science ®Google Scholar
• Scarr E, Hopper S, Vos V, et al. Low levels of muscarinic m1 receptor positive neurons in cortical layers iii and v in brodmann’s areas 9 and 17 from individuals with schizophrenia. J Psychiatry Neurosci. 2018;43:338–346.
   PubMed Web of Science ®Google Scholar
• Raedler TJ, Knable MB, Jones DW et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatr. 2003;160(1):118–127. doi: 10.1176/appi.ajp.160.1.118
   PubMed Web of Science ®Google Scholar
• Bakker G, Vingerhoets WA, van Wieringen JP, et al. 123i-iododexetimide preferentially binds to the muscarinic receptor subtype m1 in vivo. J Nucl Med. 2015;56:317–322. doi: 10.2967/jnumed.114.147488
   PubMed Web of Science ®Google Scholar
• Bakker G, Vingerhoets C, Boucherie D, et al. Relationship between muscarinic m1 receptor binding and cognition in medication-free subjects with psychosis. NeuroImage Clin. 2018;18:713–719. doi: 10.1016/j.nicl.2018.02.030
   PubMed Web of Science ®Google Scholar
• Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol. 2004;44(1):423–450. doi: 10.1146/annurev.pharmtox.44.101802.121622
   PubMedGoogle Scholar
• Wess J, Duttaroy A, Zhang W, et al. M1-m5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. ReceptorsChannels. 2003;9(4):279–290. doi: 10.3109/10606820308262
   Google Scholar
• Dean B, Scarr E. Changes in cortical gene expression in the muscarinic m1 receptor knockout mouse: potential relevance to schizophrenia, alzheimer’s disease and cognition. NPJ Schizophr. 2021;7:44. doi: 10.1038/s41537-021-00174-z
   PubMed Web of Science ®Google Scholar
• Scarr E, Udawela M, Dean B. Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia. NPJ Schizophr. 2018;4:4. doi: 10.1038/s41537-018-0044-x
   PubMed Web of Science ®Google Scholar
• Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of cns disorders. TIPS. 2009;30:148–155.
   PubMed Web of Science ®Google Scholar
• Hassani SA, Neumann A, Russell J, et al. M(1)-selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primates. Proc Natl Acad Sci U S A. 2023;120:e2216792120. doi: 10.1073/pnas.2216792120
   PubMed Web of Science ®Google Scholar
• Lange HS, Cannon CE, Drott JT, et al. The m1 muscarinic positive allosteric modulator pqca improves performance on translatable tests of memory and attention in rhesus monkeys. J Pharmacol Exp Ther. 2015;355:442–450. doi: 10.1124/jpet.115.226712
   PubMed Web of Science ®Google Scholar
• Kucinski A, Phillips KB, Koshy Cherian A, et al. Rescuing the attentional performance of rats with cholinergic losses by the m1 positive allosteric modulator tak-071. Psychopharmacol (Berl). 2020;237:137–153. doi: 10.1007/s00213-019-05354-5
   PubMed Web of Science ®Google Scholar
• Holschneider DP, Guo Y, Wang Z, et al. Positive allosteric modulation of cholinergic receptors improves spatial learning after cortical contusion injury in mice. J Neurotrauma. 2019;36:2233–2245. doi: 10.1089/neu.2018.6036
   PubMed Web of Science ®Google Scholar
• Rook JM, Bertron JL, Cho HP, et al. A novel m(1) pam vu0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity. ACS Chem Neurosci. 2018;9:2274–2285. doi: 10.1021/acschemneuro.8b00131
   PubMed Web of Science ®Google Scholar
• Puri V, Wang X, Vardigan JD, et al. The selective positive allosteric m1 muscarinic receptor modulator pqca attenuates learning and memory deficits in the tg2576 alzheimer’s disease mouse model. Behav Brain Res. 2015;287:96–99. doi: 10.1016/j.bbr.2015.03.029
   PubMed Web of Science ®Google Scholar
• Gould RW, Dencker D, Grannan M, et al. Role for the m1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice. ACS Chem Neurosci. 2015;6:1683–1695. doi: 10.1021/acschemneuro.5b00123
   PubMed Web of Science ®Google Scholar
• Abd-Elrahman KS, Sarasija S, Colson TL, et al. A positive allosteric modulator for the muscarinic receptor (m1 machr) improves pathology and cognitive deficits in female appswe/psen1deltae9 mice. Br J Pharmacol. 2022;179:1769–1783. doi: 10.1111/bph.15750
   PubMed Web of Science ®Google Scholar
• Gould RW, Russell JK, Nedelcovych MT, et al. Modulation of arousal and sleep/wake architecture by m1 pam vu0453595 across young and aged rodents and nonhuman primates. Neuropsychopharmacol. 2020;45:2219–2228. doi: 10.1038/s41386-020-00812-7
   PubMed Web of Science ®Google Scholar
• Maksymetz J, Joffe ME, Moran SP, et al. M(1) muscarinic receptors modulate fear-related inputs to the prefrontal cortex: implications for novel treatments of posttraumatic stress disorder. Biol Psychiatry. 2019;85:989–1000. doi: 10.1016/j.biopsych.2019.02.020
   PubMed Web of Science ®Google Scholar
• Walker LC, Campbell EJ, Huckstep KL, et al. M(1) muscarinic receptor activation decreases alcohol consumption via a reduction in consummatory behavior. Pharmacol Res Perspect. 2022;10:e00907. doi: 10.1002/prp2.907
   PubMed Web of Science ®Google Scholar
• Galvin VC, Yang S, Lowet AS, et al. M1 receptors interacting with nmdar enhance delay-related neuronal firing and improve working memory performance. Curr Res Neurobiol. 2021;2. doi: 10.1016/j.crneur.2021.100016
   PubMedGoogle Scholar
• McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023. doi: 10.1038/s41380-023-01949-9
   Web of Science ®Google Scholar
• Cieslik P, Domin H, Chocyk A, et al. Simultaneous activation of mglu(2) and muscarinic receptors reverses mk-801-induced cognitive decline in rodents. Neuropharmacol. 2020;174:107866. doi: 10.1016/j.neuropharm.2019.107866
   PubMed Web of Science ®Google Scholar
• Wolf DH, Zheng D, Kohler C, et al. Effect of mglur2 positive allosteric modulation on frontostriatal working memory activation in schizophrenia. Mol Psychiatry. 2022;27:1226–1232. doi: 10.1038/s41380-021-01320-w
   PubMed Web of Science ®Google Scholar
• Cieślik P, Woźniak M, Rook JM, et al. Mutual activation of glutamatergic mglu4 and muscarinic m4 receptors reverses schizophrenia-related changes in rodents. Psychopharmacol (Berl). 2018;235:2897–2913. doi: 10.1007/s00213-018-4980-y
   PubMed Web of Science ®Google Scholar
• Dogra S, Conn PJ. Metabotropic glutamate receptors as emerging targets for the treatment of schizophrenia. Mol Pharmacol. 2022;101:275–285. doi: 10.1124/molpharm.121.000460
   PubMed Web of Science ®Google Scholar
• Lange HS, Vardigan JD, Cannon CE, et al. Effects of a novel m4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to alzheimer’s disease and schizophrenia in rhesus monkey. Neuropharmacol. 2021;197:108754. doi: 10.1016/j.neuropharm.2021.108754
   PubMed Web of Science ®Google Scholar
• Gould RW, Grannan MD, Gunter BW, et al. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective m4 pam vu0467154. Neuropharmacol. 2018;128:492–502. doi: 10.1016/j.neuropharm.2017.07.013
   PubMed Web of Science ®Google Scholar
• Grauer SM, Sanoja R, Poulin D, et al. Antinociceptive effects of potent, selective and brain penetrant muscarinic m(4) positive allosteric modulators in rodent pain models. Brain Res. 2020;1737:146814. doi: 10.1016/j.brainres.2020.146814
   PubMed Web of Science ®Google Scholar
• Dall C, Weikop P, Dencker D, et al. Muscarinic receptor m(4) positive allosteric modulators attenuate central effects of cocaine. Drug Alcohol Depend. 2017;176:154–161. doi: 10.1016/j.drugalcdep.2017.03.014
   PubMed Web of Science ®Google Scholar
• Nair AG, Castro LRV, El Khoury M, et al. The high efficacy of muscarinic m4 receptor in d1 medium spiny neurons reverses striatal hyperdopaminergia. Neuropharmacol. 2019;146:74–83. doi: 10.1016/j.neuropharm.2018.11.029
   PubMed Web of Science ®Google Scholar
• Foster DJ, Wilson JM, Remke DH, et al. Antipsychotic-like effects of m4 positive allosteric modulators are mediated by cb2 receptor-dependent inhibition of dopamine release. Neuron. 2016;91:1244–1252. doi: 10.1016/j.neuron.2016.08.017
   PubMed Web of Science ®Google Scholar
• Thomsen M, Crittenden JR, Lindsley CW, et al. Effects of acute and repeated administration of the selective m(4) pam vu0152099 on cocaine versus food choice in male rats. Addict Biol. 2022;27:e13145. doi: 10.1111/adb.13145
   PubMed Web of Science ®Google Scholar
• Stoll K, Hart R, Lindsley CW, et al. Effects of muscarinic m(1) and m(4) acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning. Psychopharmacol (Berl). 2018;235:815–827. doi: 10.1007/s00213-017-4797-0
   PubMed Web of Science ®Google Scholar
• Brugnoli A, Pisano CA, Morari M. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats. Neurobiol Dis. 2020;144:105044. doi: 10.1016/j.nbd.2020.105044
   PubMed Web of Science ®Google Scholar
• Thorn CA, Moon J, Bourbonais CA, et al. Striatal, hippocampal, and cortical networks are differentially responsive to the m4- and m1-muscarinic acetylcholine receptor mediated effects of xanomeline. ACS Chem Neurosci. 2019;10:3910. doi: 10.1021/acschemneuro.9b00335
   PubMed Web of Science ®Google Scholar
• Power SK, Venkatesan S, Lambe EK. Xanomeline restores endogenous nicotinic acetylcholine receptor signaling in mouse prefrontal cortex. Neuropsychopharmacol. 2023;48:671–682. doi: 10.1038/s41386-023-01531-5
   PubMed Web of Science ®Google Scholar
• Russell JK, Ingram SM, Teal LB, et al. M(1)/m(4)-preferring muscarinic cholinergic receptor agonist xanomeline reverses wake and arousal deficits in nonpathologically aged mice. ACS Chem Neurosci. 2023;14:435–457. doi: 10.1021/acschemneuro.2c00592
   PubMed Web of Science ®Google Scholar
• Fellner C. New schizophrenia treatments address unmet clinical needs. Pharm Ther. 2017;42:130–134.
   Google Scholar
• Kaskie RE, Graziano B, Ferrarelli F. Schizophrenia and sleep disorders: Links, risks, and management challenges. Nat Sci Sleep. 2017;9:227–239. doi: 10.2147/NSS.S121076
   PubMed Web of Science ®Google Scholar
• Kavanagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002;62:743–755. doi: 10.2165/00003495-200262050-00003
   PubMed Web of Science ®Google Scholar
• Dean B. Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia. Aust NZ J Psychiatry. 2000;34:560–569.
   PubMed Web of Science ®Google Scholar
• Slifstein M, van de Giessen E, Van Snellenberg J, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015;72:316–324. doi: 10.1001/jamapsychiatry.2014.2414
   PubMed Web of Science ®Google Scholar
• Bleuler E. Demetia praecox or the groups of schizophrenias. (NY): International Press; 1950.
   Google Scholar
• Insel TR. Rethinking schizophrenia. Nature. 2010;468:187–193. doi: 10.1038/nature09552
   PubMed Web of Science ®Google Scholar
• Dean B, Moller HJ, Svensson TH, et al. Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 cinp think-tank. Int J Neuropsychopharmacol. 2013;17:137–148.
   PubMed Web of Science ®Google Scholar
• AK-M L, Lin J-J, Tseng H-H, et al. DNA methylation signature aberration as potential biomarkers in treatment-resistant schizophrenia: constructing a methylation risk score using a machine learning method. J Psychiatr Res. 2023;157:57–65. doi: 10.1016/j.jpsychires.2022.11.008
   PubMed Web of Science ®Google Scholar
• Pérez-Rodríguez D, Penedo MA, Rivera-Baltanás T, et al. Mirna differences related to treatment-resistant schizophrenia. Int J Mol Sci. 2023;24(3):1891. doi: 10.3390/ijms24031891
   PubMed Web of Science ®Google Scholar
• Scarr E, Cowie TF, Kanellakis S, et al. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry. 2009;14(11):1017–1023. doi: 10.1038/mp.2008.28
   PubMed Web of Science ®Google Scholar
• Dean B, Haroutunian V, Scarr E. Lower levels of cortical [3h]pirenzepine binding to postmortem tissue defines a sub-group of older people with schizophrenia with less severe cognitive deficits. Schizophr Res. 2023;255:174–282.
   Web of Science ®Google Scholar
• Gale EA. The discovery of type 1 diabetes. Diabetes. 2001;50:217–226.
   PubMed Web of Science ®Google Scholar
• Scarr E, Udawela M, Thomas EA, et al. Changed gene expression in subjects with schizophrenia and low cortical muscarinic m1 receptors predicts disrupted upstream pathways interacting with that receptor. Mol Psychiatry. 2018;23:295–303. doi: 10.1038/mp.2016.195
   PubMed Web of Science ®Google Scholar
• Scarr E, Craig JM, Cairns MJ, et al. Decreased cortical muscarinic m1 receptors in schizophrenia are associated with changes in gene promoter methylation, mrna and gene targeting microrna. TransPsychiatr. 2013;3:e230.
   Google Scholar
• Dean B, Thomas N, Lai CY, et al. Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia. Schizophr Res. 2015;169:83–88. doi: 10.1016/j.schres.2015.10.028
   PubMed Web of Science ®Google Scholar
• Dean B, Pavey G, Scarr E. Higher levels of α7 nicotinic receptors, but not choline acetyltransferase, in the dorsolateral prefrontal cortex from a sub-group of patients with schizophrenia. Schizophr Res. 2020;222:283–290. doi: 10.1016/j.schres.2020.05.034
   PubMed Web of Science ®Google Scholar
• Salah-Uddin H, Scarr E, Pavey G, et al. Altered m(1) muscarinic acetylcholine receptor (chrm1)-galpha(q/11) coupling in a schizophrenia endophenotype. Neuropsychopharmacol. 2009;34:2156–2166.
   PubMed Web of Science ®Google Scholar
• Dean B, Hopper S, Conn PJ, et al. Changes in bqca allosteric modulation of [3h]nms binding to human cortex within schizophrenia and by divalent cations. Neuropsychopharmacol. 2016;41:1620–1628. doi: 10.1038/npp.2015.330
   PubMed Web of Science ®Google Scholar
• Hopper S, Pavey GM, Gogos A, et al. Widespread changes in positive allosteric modulation of the muscarinic m1 receptor in some participants with schizophrenia. Int J Neuropsychopharmacol. 2019;22:640–650. doi: 10.1093/ijnp/pyz045
   PubMed Web of Science ®Google Scholar
• Scarr E, Udawela M, Greenough MA, et al. Altered expression of the zinc transporter slc39a12 suggests a breakdown in zinc cortical homeostasis as part of the pathophysiology of schizophrenia. NPJ Schizophr. 2016;2:16002. doi: 10.1038/npjschz.2016.2
   PubMedGoogle Scholar
• Terry AV, Callahan PM. Α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: update on animal and clinical studies and strategies for the future. Neuropharmacol. 2020;170:108053. doi: 10.1016/j.neuropharm.2020.108053
   PubMed Web of Science ®Google Scholar
• Rowe CC, Krishnadas N, Ackermann U, et al. Pet imaging of brain muscarinic receptors with (18)f-fluorobenzyl-dexetimide: A first in human study. Psychiatry Res Neuroimaging. 2021;316:111354. doi: 10.1016/j.pscychresns.2021.111354
   PubMed Web of Science ®Google Scholar
• Tong L, Li W, Lo MM, et al. Discovery of [(11)c]mk-6884: a positron emission tomography (pet) imaging agent for the study of m4muscarinic receptor positive allosteric modulators (pams) in neurodegenerative diseases. J Med Chem. 2020;63:2411–2425. doi: 10.1021/acs.jmedchem.9b01406
   PubMed Web of Science ®Google Scholar
• Deng X, Hatori A, Chen Z, et al. Synthesis and preliminary evaluation of (11) c-labeled vu0467485/az13713945 and its analogues for imaging muscarinic acetylcholine receptor subtype 4. ChemMedchem. 2019;14:303–309. doi: 10.1002/cmdc.201800710
   PubMed Web of Science ®Google Scholar
• Committee on Strategies for Responsible Sharing of Clinical Trial D. Board on Health Sciences P, institute of M. In: Sharing clinical trial data: maximizing benefits, minimizing risk. (WA) (DC): National Academies Press (US) Copyright 2015 by the National Academy of Sciences. All rights reserved.; 2015.
   Google Scholar
• Donati FL, D’Agostino A, Ferrarelli F. Neurocognitive and neurophysiological endophenotypes in schizophrenia: an overview. Biomark Neuropsychiatry. 2020;3:100017. doi: 10.1016/j.bionps.2020.100017
   PubMedGoogle Scholar
• Dean B, Thomas EHX, Bozaoglu K, et al. Evidence that a working memory cognitive phenotype within schizophrenia has a unique underlying biology. Psychiatry Res. 2022;317:114873. doi: 10.1016/j.psychres.2022.114873
   PubMed Web of Science ®Google Scholar